MedTrace Logo

A COPD Quality Improvement Program（QIP）

NCT05638646 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1107

Last updated 2022-12-19

No results posted yet for this study

Summary

QIP(Quality Improvement Programme) is a COPD quality improvement program in China. The initial step of this program is to set up the Quality Standards(QS) of COPD management in clinical practice, then embed Quality Standards into routine care and uses Quality Control Indicators (QCI)to check the QS implementation. The aim of the QIP program is to standardize COPD management in clinical practice in China, including the standardization of diagnosis, assessment, pharmacological and non-pharmacological intervention, and follow-up. COPD patients can benefit from standardization clinical behaviours, to be identified early, be accessed comprehensively, and be treated correctly according to guidelines, and with an appropriate follow-up to improve adherence.

Conditions

Interventions

OTHER

Intervention group

Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease

OTHER

control group

Maintain current treatment

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Shenzhen People's Hospital

    lead OTHER

Principal Investigators

  • Rongchang Chen, Professor · Shenzhen People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-25
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05638646 on ClinicalTrials.gov